Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig. Atorvastatin versus simvastatin

Biochemical Pharmacology

Volumn 58, Issue 7, 1999, Pages 1209-1219

  Conde, Karin ^a   Pineda, Graciela ^a   Newton, Roger S ^b   Fernandez, Maria Luz ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b PFIZER INC   (United States)

Author keywords

ACAT; Atorvastatin; CETP; Guinea pig; LDL fractional catabolic rates (FCR); LDL oxidation; Simvastatin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GUINEA PIG; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; LIPID TRANSPORT; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; GUINEA PIGS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER; MALE; PYRROLES; SIMVASTATIN;

EID: 0033213762     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00203-8     Document Type: Article

References (62)

1. Dietschy J.M., Turley S.D., Spady D.K. Role of the liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 34:1993;1637-1659.
2. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
3. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1992;1569-1582.
4. Davignon J., Montigny M., Dufour R. HMG-CoA reductase inhibitors A look back and a look ahead . Can J Cardiol. 8:1992;843-864.
5. Kasim S.E., LeBoeuf R.C., Khilnani S., Tallapaka L., Dayananda D., Jen L.L. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res. 33:1992;1-7.
6. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
7. Marais A.D., Firth J.C., Bateman M.E., Byrnes P., Martens C., Mountney J. Atorvastatin An effective lipid-modifying agent in familial hypercholesterolemia . Arterioscler Thromb Vasc Biol. 17:1997;1527-1531.
8. Roth B.D., Bocan T.M., Blankley C.J., Chucholowski A.W., Creger P.L., Creswell M.W., Ferguson E., Newton R.S., O'Brien P., Picard J.A. Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem. 34:1991;463-466.
9. Naoumova R.P., Dunn S., Rallidis L., Abu-Muhana O., Neuwirth C., Rendell N.B., Taylor G.W., Thompson G.R. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res. 38:1997;1496-1500.
10. Bergstrom J.D., Bostedor R.G., Rew D.J., Geissler W.M., Wright S.D., Chao Y.S. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase A comparison of atorvastatin and simvastatin . Biochim Biophys Acta. 1389:1998;213-221.
11. Cuchel M., Schaefer E.J., Millar J.S., Jones P.J.H., Dolnikowski G.G., Vergani C., Lichtenstein A.H. Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol. 17:1997;1910-1917.
12. Watts G.F., Naoumova R.P., Kelly J.M., Riches F.M., Croft K.D., Thompson G.R. Inhibition of cholesterogenesis decreases hepatic secretion of apo B-100 in normolipidemic subjects. Am J Physiol. 273:1997;E462-E470.
13. Auerbach B.J., Krause B.R., Bisgaier C.L., Newton R.S. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit Atorvastatin versus lovastatin . Atherosclerosis. 115:1995;173-182.
14. Berglund L., Sharkey M.F., Elam R.L., Witztum J.L. Effects of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism. J Lipid Res. 30:1989;1591-1600.
15. Berglund L., Witztum J.L., Galeano N.F., Khouw A.S., Ginsberg H.N., Ramakrishnan R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia Increase in receptor activity, decrease in apoB production and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach . J Lipid Res. 39:1998;913-924.
16. Malmendier C.L., Lontie J.F., Delcroix C., Magot T. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis. 80:1989;101-109.
17. Conde K., Vergara-Jimenez M., Krause B.R., Newton R.S., Fernandez M.L. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res. 37:1996;2372-2382.
18. Aviram M. Oxidative modification of LDL and its relation to atherosclerosis. Isr J Med Sci. 31:1995;241-249.
19. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 13:1993;815-825.
20. Krause B.R., Newton R.S. Animal models for the evaluation of inhibitors of HMG-CoA reductase. Adv Lipid Res. 1:1991;57-72.
21. Lin E.C.K., Fernandez M.L., McNamara D.J. Dietary cholesterol and fat quantity interact to affect cholesterol metabolism in guinea pigs. J Nutr. 120:1992;1037-1045.
22. Redgrave T., Roberts C., West C. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 65:1975;42-49.
23. Redgrave T.G., Carlson L.A. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res. 20:1979;217-229.
24. Allain C., Poon L., Chan C., Richmond W., Fu P. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475.
25. 2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
26. Carr T.P., Andressen C.J., Rudel L.L. Enzymatic determination of triacylglycerol, free cholesterol and cholesterol in tissue lipid extracts. Clin Biochem. 26:1993;39-42.
27. Folch J., Lees M., Sloan-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 226:1957;497-509.
28. Fernandez M.L., Vergara-Jimenez M., Conde K., Behr T., Abdel-Fattah G. Regulation of apolipoprotein B-containing lipoproteins by dietary soluble fiber in guinea pigs. Am J Clin Nutr. 65:1997;814-822.
29. Ogawa Y., Fielding C. Assay of cholesteryl ester transfer activity and purification of a cholesteryl ester transfer protein. Methods Enzymol. 11:1985;274-285.
30. Ishida B.Y., Paigen B. Silver-enhanced radial immunodiffusion assay of plasma apolipoproteins. J Lipid Res. 33:1992;1073-1078.
31. Markwell M.A., Haas S., Bieber L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 87:1978;206-210.
32. Puhl H., Waeg G., Esterbauer H. Methods to determine oxidation of low density lipoproteins. Methods Enzymol. 233:1994;425-441.
33. Fernandez M.L., Sun D.M., Montano C., McNamara D.J. Carbohydrate-fat exchange and regulation of hepatic cholesterol and plasma lipoprotein metabolism in the guinea pig. Metabolism. 44:1995;855-864.
34. Smith J.L., Jersey J., Pillay S.P., Hardie I.R. Hepatic acyl-CoA:cholesterol acyltransferase. Development of a standard assay and determination in patients with cholesterol gallstones. Clin Chim Acta. 158:1986;271-282.
35. Goldstein J.L., Basu S.K., Brown M.S. Receptor mediated endocytosis of low density lipoprotein in cultured cells. Methods Enzymol. 98:1983;241-260.
36. Khouw A.S., Parthasarathy S., Witztum J.L. Radioiodination of low density lipoprotein initiates lipid peroxidation Protection by use of antioxidants . J Lipid Res. 34:1993;1483-1496.
37. 131I-labelled plasma proteins. Phys Med Biol. 2:1957;36-68.
38. Fernandez M.L. Distinct mechanisms of plasma LDL lowering by dietary fiber in the guinea pig Specific effects of pectin, guar gum, and psyllium . J Lipid Res. 36:1995;2394-2404.
39. Bocan T.M., Ferguson E., McNally W., Uhlendorf P.D. Bak Mueller S, Dehart P, Sliskovic DR, Roth BD, Krause BR and Newton RS, Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981 Comparison with selected HMG-CoA reductase inhibitors . Biochim Biophys Acta. 1123:1992;133-144.
40. Gibson D.M., Bron N.J., Richens A., Hounslow N.J., Sedman A.J., Whitfield L.R. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J ClinPharmacol. 36:1996;242-246.
41. Cilla D.D., Gibson D.M., Whitfield L.R., Sedman A.J. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 36:1996;604-609.
42. Radulovic L.L., Cilla D.D., Posvar E.L., Sedman A.J., Whitfield L.R. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol. 35:1995;990-994.
43. Bisgaier C.L., Essenburg A.D., Auerbach B.J., Pape M.E., Sekerke C.S., Gee A., Wolle S., Newton R.S. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res. 38:1998;2502-2515.
44. Homma Y., Ozawa H., Kobayashi T., Yamaguchi H., Sakane H., Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis. 114:1995;223-234.
45. Gaw A., Packard C.J., Murray E.F., Lindsay G.M., Griffin B.A., Caslake M.J., Vallance B.D., Lorimer A.R., Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb. 13:1993;170-189.
46. Watts G.F., Cummings M.H., Umpleby M., Quiney J.R., Naoumova R., Thompson G.R., Sonksen P.H. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia Pathophysiological and therapeutic implications . Eur J Clin Invest. 25:1995;559-567.
47. Alaupovic P., Heinonen T., Shurzinske L., Black D.M. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triacylglycerol levels. Atherosclerosis. 133:1997;123-133.
48. Owens D., Collins P., Johnson A., Tighe O., Robinson K., Tomkin G.H. Hypercholesterolemia, Simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Biochim Biophys Acta. 1082:1991;303-309.
49. Yuan J.N., Tsai M.Y., Hegland J., Hunninghake D.E. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 87:1991;147-157.
50. Aviram M., Rosenbalt M., Bisgaier C.L., Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 138:1998;271-280.
51. Steinberg D.S., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol, Modifications of LDL that increase its atherogenicity. N Engl J Med. 320:1989;915-924.
52. Kaplan M., Aviram M. Oxidized LDL binding to a macrophage secreted extracellular matrix. Biochem Biophys Res Commun. 237:1997;271-276.
53. Giroux L.M., Davignon J., Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1165:1993;335-338.
54. Suckling K.E., Stange E.F. Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res. 26:1985;647-671.
55. Carr T.P., Parks J.S., Rudel L.L. Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl ester enrichment and coronary artery atherosclerosis. Arterioscler Thromb. 12:1992;1274-1283.
56. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 80:1983;4124-4128.
57. Parhofer K.G., Barrett P.H., Dunn J., Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Invest. 71:1993;939-946.
58. Burnett J.R., Telford D.E., Kleinstiver S.J., Barrett P.H.R., Newton R.S., Huff M.W. Atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 11:1997;2589-2600.
59. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 38:1997;2071-2078.
60. Ginsberg H.N. Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am. 19:1990;211-227.
61. Davignon J. Atorvastatin A statin with a large spectrum of action . Atherosclerosis. 2:1997;243-252.
62. Castaner J.G. Atorvastatin calcium. Hypolipidemic HMG-CoA reductase inhibitor. Drugs Future. 22:1997;956-968.